This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Friday, April 15, 2016
ILC2016 Coverage: Impact of Viekirax (ombitasvir/parataprevir/ritonavir and Exviera (dasabuvir) Real-world experience with 3-D regimen lives up to phase 3 studies
Watch Video
Real-world experience with 3-D regimen lives up to phase 3 studies
BARCELONA — In this video perspective from the International Liver Congress 2016, Heiner Wedemeyer, MD, research group leader, department of gastroenterology, hepatology and endocrinology at Hannover Medical School in Germany, discusses his real-world experience with the German Hepatitis C-Registry. Specifically, Wedemeyer looked at the impact of Viekirax (ombitasvir/parataprevir/ritonavir, AbbVie) and Exviera (dasabuvir, AbbVie), together known as Viekira Pak in the United States, in his own practice, showing that the everyday impact is similar to that seen in phase 3 trials.
Visit Healio.com/Hepatology to read the latest news from the meeting, or visit Highlights from ILC 2016 and follow our live updates on Twitter at @HealioHep
See more from Highlights from International Liver Congress
No comments:
Post a Comment